相关临床试验
1285
169 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
终止
17
1.3%
招募中
263
20.5%
暂停
8
0.6%
撤回
7
0.5%
进行中（未招募）
61
4.8%
Unknown
220
17.1%
已完成
601
46.8%
Enrolling By Invitation
13
1.0%
尚未招募
95
7.4%
暂无批准数据
- Researchers at The University of Hong Kong developed a light-driven method using copper(I) photosensitisers to construct bicyclo[2.1.1]hexanes (BCHs), three-dimensional alternatives to flat benzene rings in drug molecules. - The new approach suppresses unwanted polymerisation and expands the range of starting materials to include electron-deficient alkenes, enynes, dienes, and aliphatic alkenes. - BCH scaffolds may improve drug properties such as solubility, selectivity, and metabolic stability, offering medicinal chemists greater flexibility in designing new candidates. - The team demonstrated gram-scale synthesis and further functionalisation of BCHs, highlighting the method's potential for medicinal chemistry and drug development.
- A randomized trial of the SUPPORT+ app showed patients with advanced cancer in palliative care maintained superior quality of life over 18 weeks compared with usual care (P < .001). - The PRO B digital care concept, tested across 52 German breast cancer centers and 909 patients, significantly reduced fatigue and improved physical functioning in metastatic breast cancer. - Both interventions reduced unplanned hospitalizations, with the SUPPORT+ group showing a significantly lower rate of worsening hospitalization episodes (17.2% vs. 28.5%; OR = 0.52). - Germany's Federal Joint Committee (G-BA) recommended incorporating the PRO B concept into standard care, with rollout under the name "ida" expected this autumn.
- AilsynBio, an AI-driven drug discovery company, signed a project cooperation agreement with Dong-E-E-Jiao Co., Ltd. to integrate artificial intelligence with traditional Chinese medicine development. - The partnership will focus on three key areas: advancing AI-driven innovation in drug discovery, launching specialized research on Premature Ovarian Insufficiency (POI), and promoting cross-border fusion of biotechnology with traditional medicine. - The collaboration aims to transform traditional Chinese medicine from empirical medicine to evidence-based medicine, with specific focus on strengthening the scientific foundation of Compound E-Jiao Syrup for women's health applications. - The agreement was signed at Hong Kong Science Park and witnessed by senior representatives from China Resources Pharmaceutical Group, Hong Kong Science and Technology Parks Corporation, and The University of Hong Kong.
